Seres Therapeutics, Inc.

Contributing Author

Recent Articles by Seres Therapeutics, Inc.

Nov-04	Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) MCRB +6.63% GlobeNewswire
Nov-03	Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients MCRB +7.10% GlobeNewswire
Oct-15	Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 MCRB GlobeNewswire
Sep-08	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MCRB MCRB -5.04% GlobeNewswire
Sep-01	Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference MCRB +5.50% GlobeNewswire
Aug-05	Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs MCRB GlobeNewswire
Jul-08	Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment MCRB -12.29% GlobeNewswire
Jun-25	Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis MCRB GlobeNewswire
Jun-05	Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 MCRB GlobeNewswire
May-12	Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference MCRB GlobeNewswire
May-05	Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates MCRB GlobeNewswire
May-04	Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease MCRB GlobeNewswire
Apr-20	Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 MCRB GlobeNewswire
Apr-20	Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 MCRB GlobeNewswire
Apr-09	Seres Therapeutics to Present at CARB-X Investor Day MCRB GlobeNewswire
Mar-12	Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates MCRB GlobeNewswire
Mar-02	Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates MCRB GlobeNewswire
Feb-12	Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases MCRB -41.66% GlobeNewswire
Jan-06	Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy MCRB GlobeNewswire
Nov-24	Seres Therapeutics to Participate in Piper Sandler Healthcare Conference MCRB GlobeNewswire
Nov-05	Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates MCRB -7.64% GlobeNewswire
Oct-30	Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 MCRB -6.57% GlobeNewswire
Oct-29	Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 MCRB GlobeNewswire
Oct-14	Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant MCRB GlobeNewswire
Sep-23	Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway MCRB +6.30% GlobeNewswire
Aug-27	Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference MCRB GlobeNewswire
Aug-06	Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates MCRB GlobeNewswire
Jul-22	Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 MCRB -10.54% GlobeNewswire
Jul-22	Seres Therapeutics Announces Leadership Transition MCRB -10.54% GlobeNewswire
May-27	Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting MCRB -5.74% GlobeNewswire
May-07	Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates MCRB GlobeNewswire

Seres Therapeutics, Inc.

Recent Articles by Seres Therapeutics, Inc.

Upgrade your Finviz experience